Combinatorial targeting of FGF and ErbB receptors blocks growth and metastatic spread of breast cancer models

INTRODUCTION: Targeting receptor tyrosine kinases (RTKs) with kinase inhibitors is a clinically validated anti-cancer approach. However, blocking one signaling pathway is often not sufficient to cause tumor regression and the effectiveness of individual inhibitors is often short-lived. As alteration...

Descripción completa

Detalles Bibliográficos
Autores principales: Issa, Amine, Gill, Jason W, Heideman, Marinus R, Sahin, Ozgur, Wiemann, Stefan, Dey, Julien H, Hynes, Nancy E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3672810/
https://www.ncbi.nlm.nih.gov/pubmed/23343422
http://dx.doi.org/10.1186/bcr3379

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3672810/
https://www.ncbi.nlm.nih.gov/pubmed/23343422
http://dx.doi.org/10.1186/bcr3379

Ejemplares similares